Milestone Achievement for Hospital Using Catheter Precision’s VIVO System
Catheter Precision (NYSE:VTAK) announced that the Heart Hospital of New Mexico has achieved a significant milestone by completing 200 ventricular ablation procedures using the company's VIVO system. The Heart Hospital, part of the Lovelace Health system, is New Mexico's only hospital dedicated exclusively to cardiovascular care.
The Lovelace Health system encompasses five hospitals, 33 health care clinics, and seven outpatient therapy clinics with over 300 healthcare providers. The hospital's physician team has published data and facilitated educational initiatives for other physicians regarding the VIVO technology.
Catheter Precision (NYSE:VTAK) ha annunciato che il Heart Hospital del New Mexico ha raggiunto un importante traguardo completando 200 procedure di ablazione ventricolare utilizzando il sistema VIVO dell'azienda. Il Heart Hospital, parte del sistema sanitario Lovelace Health, è l'unico ospedale del New Mexico dedicato esclusivamente alla cura cardiovascolare.
Il sistema sanitario Lovelace Health comprende cinque ospedali, 33 cliniche sanitarie e sette cliniche di terapia ambulatoriale con oltre 300 operatori sanitari. Il team medico dell'ospedale ha pubblicato dati e promosso iniziative educative per altri medici riguardo alla tecnologia VIVO.
Catheter Precision (NYSE:VTAK) anunció que el Heart Hospital de Nuevo México ha alcanzado un hito significativo al completar 200 procedimientos de ablación ventricular utilizando el sistema VIVO de la compañía. El Heart Hospital, que forma parte del sistema Lovelace Health, es el único hospital en Nuevo México dedicado exclusivamente al cuidado cardiovascular.
El sistema Lovelace Health incluye cinco hospitales, 33 clínicas de atención médica y siete clínicas de terapia ambulatoria con más de 300 proveedores de salud. El equipo médico del hospital ha publicado datos y facilitado iniciativas educativas para otros médicos sobre la tecnología VIVO.
Catheter Precision (NYSE:VTAK)는 뉴멕시코 하트 병원이 자사의 VIVO 시스템을 사용하여 200건의 심실 절제술을 성공적으로 완료하는 중요한 이정표를 달성했다고 발표했습니다. 하트 병원은 Lovelace Health 시스템의 일부로, 뉴멕시코에서 심혈관 치료에 전념하는 유일한 병원입니다.
Lovelace Health 시스템은 5개의 병원, 33개의 의료 클리닉, 7개의 외래 치료 클리닉을 포함하며 300명 이상의 의료 제공자가 근무하고 있습니다. 병원의 의료진은 VIVO 기술과 관련된 데이터를 발표하고 다른 의사들을 위한 교육 활동을 지원해왔습니다.
Catheter Precision (NYSE:VTAK) a annoncé que le Heart Hospital du Nouveau-Mexique a franchi une étape importante en réalisant 200 procédures d'ablation ventriculaire à l'aide du système VIVO de la société. Le Heart Hospital, qui fait partie du système Lovelace Health, est le seul hôpital du Nouveau-Mexique entièrement dédié aux soins cardiovasculaires.
Le système Lovelace Health comprend cinq hôpitaux, 33 cliniques de santé et sept cliniques de thérapie ambulatoire avec plus de 300 professionnels de santé. L'équipe médicale de l'hôpital a publié des données et organisé des initiatives éducatives pour d'autres médecins concernant la technologie VIVO.
Catheter Precision (NYSE:VTAK) gab bekannt, dass das Heart Hospital von New Mexico einen bedeutenden Meilenstein erreicht hat, indem es 200 ventrikuläre Ablationsverfahren mit dem VIVO-System des Unternehmens abgeschlossen hat. Das Heart Hospital, Teil des Lovelace Health Systems, ist das einzige Krankenhaus in New Mexico, das sich ausschließlich der kardiovaskulären Versorgung widmet.
Das Lovelace Health System umfasst fünf Krankenhäuser, 33 Gesundheitskliniken und sieben ambulante Therapiepraxen mit über 300 Gesundheitsdienstleistern. Das Ärzteteam des Krankenhauses hat Daten veröffentlicht und Bildungsinitiativen für andere Ärzte zur VIVO-Technologie gefördert.
- First hospital to reach 200 VIVO system procedures, demonstrating product adoption
- Hospital's publication of data and educational initiatives supports VIVO's credibility
- None.
Heart Hospital of New Mexico is the First Hospital to Complete 200 Ventricular Ablation Procedures with the VIVO System
FORT MILL, S.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that the Heart Hospital of New Mexico is the first customer to complete 200 ventricular ablation procedures using its VIVO system.
Heart Hospital of New Mexico is part of the Lovelace Health system which is made up of five hospitals, 33 health care clinics and seven outpatient therapy clinics with over 300 healthcare providers. The Heart Hospital of New Mexico at Lovelace Medical Center is New Mexico’s only hospital dedicated exclusively to cardiovascular care.
David Jenkins, CEO of Catheter Precision said, “We are excited to congratulate the Heart Hospital of New Mexico on celebrating their 200th procedure utilizing VIVO. VIVO is a tool that is designed to help physicians and as one of the first users of VIVO, the physician team has fully embraced the technology. They have published their data and welcomed physicians for educational purposes and their partnership and support of the VIVO product line is invaluable. We look forward to their continued use and seeing what other milestone achievements they accomplish!”
About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
Attachment
FAQ
How many VIVO system procedures has Heart Hospital of New Mexico completed?
What is the significance of Heart Hospital of New Mexico's achievement with VTAK's VIVO system?
What is the size of the Lovelace Health system where the VIVO procedures were performed?
What makes the Heart Hospital of New Mexico unique in cardiovascular care?
